At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Vehicle +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ATI-50002 Topical Solution Administered Twice-Daily for 28 Days in Adult Subjects With Alopecia Universalis and Alopecia Totalis With a 12-Month Long-Term Open-Label Extension
In Brief
A Phase 2 clinical trial evaluating Vehicle and ATI-50002 for Alopecia Universalis (AU) and Alopecia Totalis (AT). Completed, enrolled 11 participants across 2 sites.
Detailed Summary
The primary objective is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution compared to vehicle in subjects with AU and AT.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Universalis (AU), Alopecia Totalis (AT)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartDec 2017
Primary CompletionJun 2019
TodayJul 2026
First PostedOct 20, 2017
Enrollment StartDec 14, 2017
Primary CompletionJun 20, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.7 years ago
Interventions
Vehicledrug
Vehicle Topical Solution
ATI-50002drug
ATI-50002 Topical Solution